AXNX - Axonics' new sacral neuromodulation system gets FDA approval

• The U.S. Food and Drug Administration (FDA) approved Axonics ( NASDAQ: AXNX ) fourth-generation rechargeable sacral neuromodulation system (SNM).
• SNM is a therapy to treat urinary incontinence.
• The company said Axonics R20 neurostimulator is labeled for a functional life in the body of at least 20 years and reduces how frequently a patient needs to recharge their implanted device to just once every 6 to 10 months for one hour, compared to the third-generation's recharge interval of once a month for one hour.
• Axonics plans to commercially launch the product in the U.S. in March.
• "Patients with overactive bladder tell us that first and foremost, they value efficacy and a long-lived solution to address their chronic condition," said John Woock, executive vice president, chief marketing and strategy officer, Axonics.

For further details see: